Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs
08:53am, Monday, 28'th Oct 2024
Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S.-based biotech fir
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
07:50pm, Saturday, 26'th Oct 2024
Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 glomerulop
NVS vs. LLY: Which Stock Is the Better Value Option?
12:41pm, Friday, 25'th Oct 2024
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks is more attractive to value in
What To Expect When Novartis Reports Q3 2024 Results
09:10am, Friday, 25'th Oct 2024
Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
10:21am, Thursday, 24'th Oct 2024
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for
3 Absurdly Cheap Stocks That Pay High Dividends
08:15am, Thursday, 24'th Oct 2024
These stocks are trading at less than 15 times their expected future profits.
Basel, October 24, 2024 – This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast cancer were updated to recommend ribociclib (Kisqali®) as a Category 1 preferr
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Wednesday, 23'rd Oct 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
09:35am, Tuesday, 22'nd Oct 2024
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
02:56pm, Monday, 21'st Oct 2024
The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment
Basel, October 18, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommende
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
08:45am, Thursday, 17'th Oct 2024
Novartis is taking a more calculated and strategic approach to its growth.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:01am, Wednesday, 16'th Oct 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Novartis (NVS) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 15'th Oct 2024
Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
